However, for MVO, we identified a large interaction between treatment and baseline TIMI, whereby a statistically significant treatment benefit of intracoronary adenosine was found for patients with TIMI 2/3 flow at baseline and a nonstatistically significant benefit was found for the TIMI 0/1 group.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}